Search company, investor...

Galapagos Genomics,

Founded Year




Total Raised


Date of IPO


About Galapagos Genomics

Developer of a functional genomics platform that consists of the construction and screening of adenoviral knock-in and knock-down libraries for the discovery and validation of novel drug targets and therapeutic genes. The screening of the libraries is performed in human cell-based and phenotypic functional assays. Both the construction and the screening of the libraries are set up in a high-throughput, automated and arrayed format. The phenotypic selection libraries are used both for internal discovery activities as well as in collaboration agreements with partners. The company is focused on the rapid identification and validation of disease modifying drug targets by functional screening in human disease models. Research activities encompass the internal programs in osteoporosis, rheumatoid arthritis, osteoarthritis, and Alzheimer's disease, as well as partnerships with pharmaceutical, nutraceutical, and biotech companies. Proprietary targets resulting from internal programs are used for the development of drugs in core disease areas, combined with selected out-licensing and partnering of projects during development.

Headquarters Location

Industriepark Mechelen Noord Generaal De Wittelaan L11 A3

Mechelen, 2800,


32 153 429 00

Missing: Galapagos Genomics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Galapagos Genomics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Galapagos Genomics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Galapagos Genomics is included in 1 Expert Collection, including Omics.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Galapagos Genomics Frequently Asked Questions (FAQ)

  • When was Galapagos Genomics founded?

    Galapagos Genomics was founded in 1999.

  • Where is Galapagos Genomics's headquarters?

    Galapagos Genomics's headquarters is located at Industriepark Mechelen Noord, Mechelen.

  • What is Galapagos Genomics's latest funding round?

    Galapagos Genomics's latest funding round is IPO.

  • How much did Galapagos Genomics raise?

    Galapagos Genomics raised a total of $27.78M.

  • Who are the investors of Galapagos Genomics?

    Investors of Galapagos Genomics include Crucell, AlpInvest Partners, Burrill & Company, Abingworth and Tibotec, Virco.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.